Skip to Main Content

Paper Details

Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia.
Pediatr Blood Cancer
2
2021
AML, Lenalidomide, R, acute myeloid leukemia, anemia, blast, del(5q), febrile neutropenia, hematopoietic stem cell, hypokalemia, lenalidomide, myelodysplastic syndromes, patient, patients, pediatric, pediatric AML, thrombocytopenia, white blood cell
Author NameAffiliation
Todd A AlonzoKeck School of Medicine, University of Southern California
Todd A AlonzoKeck School of Medicine, University of Southern California
Patrick BrownThe Johns Hopkins Hospital
Patrick BrownThe Johns Hopkins Hospital
Edward A KolbNemours Center for Cancer and Blood Disorders, Alfred I. duPont Hospital for Children
  • 1 - 5

Datasets

Release 1.2